Ai In Drug Screening Market: Market Size & Forecast 2026

AI in drug screening refers to the use of artificial intelligence technologies such as machine learning, deep learning, and natural language processing to identify, evaluate, and prioritize drug candidates more efficiently than conventional high-throughput screening approaches. The market reached approximately USD 3.47 billion in 2025 and is currently estimated at around USD 4.257 billion in 2026, forecast to grow at 22.68% annually through 2031, placing it on a robust growth trajectory over the forecast horizon. Comparable AI-in-drug-discovery market estimates from public sources range from about USD 1.17 billion to USD 3.8 billion in 2025, with CAGR projections spanning roughly 16% to 30.5%, underscoring strong consensus that the segment is in a high-growth phase.

Escalating R&D costs and the high attrition rate of drug candidates in late-stage clinical trials are pushing pharmaceutical companies to adopt AI-driven screening to fail faster and cheaper. The expansion of biomedical big data, including omics datasets, chemical libraries, and electronic health records, is providing the training substrate needed for more accurate predictive models. Additionally, growing demand for personalized medicine and shorter development timelines is encouraging partnerships between biopharma firms and AI technology providers.

The market can be segmented by component into software, services, and hardware infrastructure, and by application into target identification, hit identification, lead optimization, toxicity prediction, and drug repurposing. Technology segmentation typically distinguishes machine learning, deep learning, and natural language processing approaches, with machine learning representing the largest share. North America, particularly the United States, currently leads the market due to its concentration of pharmaceutical companies, AI startups, and research institutions, while Asia-Pacific is the fastest-growing region supported by expanding biotech activity in China, India, and South Korea.

What are the recent trends and outlook?

Generative AI models for de novo molecule design, foundation models trained on chemical and biological data, and automated laboratory robotics integrated with AI screening are emerging as defining trends through the late 2020s. Regulatory engagement around AI-validated drug candidates is also maturing, with agencies issuing guidance on the use of computational evidence in submissions. Looking ahead, the market is expected to continue compounding at roughly 20% to 25% annually through 2031, with consolidation likely as larger technology and pharmaceutical players acquire specialized AI-screening capabilities.